6 researched Quota Design entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer Biotech B2B sales orgs -- the CROs, eClinical software vendors, central labs, and trial-services firms selling into clinical trials -- cannot use the SaaS quota playbook, because the thing they sell takes 18 to 48 months to co…
Read full answer ↗TL;DR: When a founder and a hired sales lead/team sell in parallel, do not put the founder on a standard rep comp plan — the founder's incentive is the cap table, not a 50/50 OTE, and forcing them into quota math distorts credit, forecast, …
Read full answer ↗Direct Answer Snowflake's 3,500+ quota-carrying AEs face unprecedented churn pressure from consumption-pricing quota inflation, AI-native startup poaching, and Databricks' aggressive recruiting. Retention in 2027 hinges on four levers: (1) …
Read full answer ↗The Problem Account sizing creates rep friction. Sellers fear losing commission by moving up-market or down-market. You need two things: clear territory rules and margin-based incentives that make the split profitable for both tiers. The Se…
Read full answer ↗Separate carve-out wins for the first 90-180 days, then fold into base quota once attach rate, win rate, and discount depth all stabilize within 10% of forecast. Isolating new-product revenue from legacy quota prevents cannibalization, pres…
Read full answer ↗Segment-specific quotas and commission rates. SMB AE: $600k quota at 10% commission. Enterprise AE: $200k quota at 20% commission. Same OTE (~$120k variable), different paths. Don't use one-size-fits-all commission; reps in low-ACV segments…
Read full answer ↗